Hutchison China Meditech Limited Blocklisting Six Monthly Return (9294S)
December 29 2016 - 1:40AM
UK Regulatory
TIDMHCM
RNS Number : 9294S
Hutchison China Meditech Limited
29 December 2016
Blocklisting Six Monthly Return
London: Thursday, December 29, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following
blocklisting six monthly return:
1. Name of applicant: Hutchison China MediTech Limited
2. Name of scheme: Hutchison China MediTech Limited Share Option Schemes
3. Period of return: From June 29, 2016 to December 28, 2016
4. Balance under scheme from previous return: 1,417,789 ordinary shares of US$1 each
5. The amount by which the block scheme has been Nil
increased, if the scheme has been increased
since the date of the last return:
6. Number of securities issued/allotted under scheme 56,481 ordinary shares of US$1 each
during period:
7. Balance under scheme not yet issued/allotted at end of 1,361,308 ordinary shares of US$1 each
the period:
8. Number and class of securities originally listed and 2,560,606 ordinary shares of US$1 each admitted on
the date of admission: June 26, 2007
9. Total number of securities in issue at the end of the 60,705,823 ordinary shares of US$1 each
period:
Name of contact: Christian Hogg
Address of contact: 21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact: +852 2121 8200
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRUKUBRNAAUURA
(END) Dow Jones Newswires
December 29, 2016 02:40 ET (07:40 GMT)